Plasma Exchange in Severe Attacks of Neuromyelitis Optica Mickael Bonnan 1 and Philippe Cabre 2 1 Service de Neurologie, Hopital F.
Naznin A.
? NARCOMS Report-2007 Registry Update Optic Neuritis in Multiple Sclerosis ? Neuromyelitis Optica Dean M. Wingerchuk, MD, MSc, FRCP(C) A Historical Perspective on NMO Neuromyelitis optica (NMO), also known as Devic’s disease, was identified more than one hundred years ago as a severe disorder affecting the spinal cord (causing paralysis) and both optic nerves (causing blindness).
We report two patients, both with a history of gastric surgery, who presented with progressive optic neuropathy and myelopathy. The patients’ symptoms were initially attributed to vitamin B12 deficiency and/or neuromyelitis optica; however, after the neurologic deficits continued to progress with the use of conventional treatments, further evaluation was initiated, and a severe copper deficiency was revealed.
Neuromyelitis optica (NMO) is characterized by the association of optic neuritis and myelitis without any other neurological signs. In 30 % of the cases, NMO is associated with a systemic disorders.
Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system that causes severe optic neuritis and myelitis attacks. It tends to spare the brain early in the disease course. Characteristics of NMO that help to distinguish it from classical MS include:? (1)more severe optic neuritis and myelitis attacks; (2) prominent CSF pleocytosis (more than 50 WBC) that can be dominated by polymorphonuclear cells1-3;?(3)?lower frequency of CSF oligoclonal banding (15-30% compared with 85% in MS)1-3; and (4)?at disease onset, the brain MRI scan is normal or reveals nonspecific white matter lesions that do not meet MS MRI diagnostic criteria.
Neuromyelitis optica (NMO) is a severe inflammatory demyelinating disease often associated with a highly specific autoantibody, aquaporin-4 antibody.
BACKGROUND: Under the therapeutic point of view, neuromyelitis optica (NMO) poses major challenges. Patients with NMO manifest severe disability from recurrent demyelinating lesions and the therapies are only partially effective. We performed a retrospective analysis of the records of patients followed at our institution and provide suggestions for management of acute relapses and preventive therapy.
Neuromyelitis optica (NMO) is an inflammatory/demyelinating disorder predominantly affecting the optic nerves and spinal cord. Recent findings showed an underlying humoral abnormality in NMO, characterized by a serum antibody against aquaporin-4 (Aqp-4-Ab). In this study, we evaluated the Aqp-4-Ab status among Turkish patients with NMO to determine the clinical and prognostic relevance
Abstract: Neuromyelitis optica (NMO), or Devic disease, has been distinguished from multiple sclerosis (MS) by the presence of optic neuritis that is usually bilateral, simultaneous, and often severe, myelopathic findings accompanied by longitudinally extensive spinal cord imaging abnormalities, no brain imaging abnormalities typical of MS, and often rapid progression to debility and even death. Researchers at the Mayo Clinic have identified an immunoglobulin marker of NMO (the NMO antibody) that binds selectively to the aquaphorin-4 water channel and may play a causative role
Objective: To describe the clinical characteristics, course, and prognosis of optic neuritis in recurrent neuromyelitis optica.
BACKGROUND: Interferon-β-1b (IFNβ-1b) has been used to prevent exacerbation of relapsing-remitting multiple sclerosis (RRMS) including optic-spinal multiple sclerosis (OSMS) in Japan. We encountered 2 patients with OSMS with unexpectedly severe exacerbation soon after the initiation of IFNβ-1b therapy. The experience urged us to retrospectively review the patients with RRMS who had been treated with IFNβ-1b to identify similar cases.